Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...

today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients ...

Overall response rate (ORR) was 97% (114/117) with a complete response/stringent complete response (CR/sCR) rate of 68% (79/117) and a very good partial response or higher (>VGPR) rate of 85% (100/117 ...

(NASDAQ: ACLX) has just released new positive data from its pivotal phase 2 immagine-1 study of Anitocabtagene Autoleucel ...

The multiple myeloma armamentarium is large and getting larger. That makes treatment choices complex and the cost of ...

Researchers uncover corneal changes in multiple myeloma patients treated with belantamab mafodotin, revealing potential ...

Treatment with cemsidomide resulted in notable responses at multiple dose levels for patients with multiple myeloma ...

In 1980, Drs. Robert Kyle and Philip Greipp, Mayo Clinic hematologists, coined the term "smoldering multiple myeloma" to describe an accumulation of abnormal plasma cells in the bone marrow ...

This important designation was granted for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy including a ...